Tolero Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for serious oncological and hematological diseases. Its lead program, alvocidib, is a potent small-molecule CDK inhibitor being developed as a front-line combination therapy for AML and relapsed/refractory AML and has shown high complete response rates in clinical studies to date. The company plans to initiate Phase 3 clinical trials of alvocidib in patients with AML in 2015. Proceeds from the Series B financing will support the further development and commercialization of alvocidib. Tolero also intends to advance its preclinical pipeline and plans to initiate clinical trials of two preclinical programs in 2015. The company is advancing both clinical and preclinical programs to address leukemias, anemia, and targets of drug resistance and transcriptional control. Tolero Pharmaceuticals is advancing a pipeline of therapies targeting oncological and hematological diseases, with a lead program focused on acute myeloid leukemia (AML). Its lead asset, alvocidib, is a potent small-molecule inhibitor of cyclin-dependent kinases (CDKs) being developed as a front-line combination therapy for AML and relapsed/refractory AML. The company intends to initiate a Phase 3 clinical trial of alvocidib in patients with AML in 2015. Proceeds from the recent financing will support further development and commercialization of alvocidib and the ongoing advancement of Tolero’s preclinical pipeline. Tolero frames its programs around targets related to blood disorders, drug resistance, and transcriptional control. The company is headquartered in Salt Lake City.

Total raised

$37M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2014